Education
About Us
Working with TipRanks
Follow Us
Biofrontera (BFRI)
NASDAQ:BFRI
BFRI Stock Chart & Stats
$0.74
$0.09(8.11%)
At close: 4:00 PM EST
$0.74
$0.09(8.11%)
Day’s Range― - ―
52-Week Range$0.54 - $1.19
Previous CloseN/A
Volume12.39M
Average Volume (3M)120.49K
Market Cap
$10.13M
Enterprise Value$9.90M
Total Cash (Recent Filing)$6.39M
Total Debt (Recent Filing)$6.16M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
May 08, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding11,648,323
10 Day Avg. Volume72,915
30 Day Avg. Volume120,486
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.55
Price to Sales (P/S)0.14
P/FCF Ratio-0.43
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue0.24
Enterprise Value/Gross Profit0.31
Enterprise Value/Ebitda-0.95
Forecast
1Y Price Target
$9.00Price Target Upside1116.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.12
Revenue Forecast (FY)$45.65M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutsData from the Phase 3 extremities trial and the Phase 2b acne trial expected early in 2026 could validate new indications and materially expand commercial opportunity.
Operational Cost SavingsRestructuring of agreements with former parent Biofrontera AG is expected to deliver cost savings and operational efficiencies that improve margins and cash flow flexibility.
Regulatory FilingA supplemental NDA submission for the extremities indication projected in mid-2026 could enable label expansion and broader prescribing, supporting future revenue growth.
Bears Say
Demand Timing VolatilityCustomer stockpiling ahead of an anticipated price increase could create a pull-forward effect, producing revenue volatility once the stocking period ends.
Profitability PressureA larger-than-planned net loss underscores ongoing profitability challenges that could weigh on the stock until margins show sustained improvement.
Top-line Momentum RiskIn-line quarterly revenue suggests limited top-line momentum, increasing the risk that growth expectations may not be met.
Biofrontera News
BFRI FAQ
What was Biofrontera’s price range in the past 12 months?
Biofrontera lowest stock price was $0.54 and its highest was $1.19 in the past 12 months.
What is Biofrontera’s market cap?
Biofrontera’s market cap is $10.13M.
When is Biofrontera’s upcoming earnings report date?
Biofrontera’s upcoming earnings report date is May 08, 2026 which is in 46 days.
How were Biofrontera’s earnings last quarter?
Biofrontera released its earnings results on Mar 19, 2026. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.195 by $0.285.
Is Biofrontera overvalued?
According to Wall Street analysts Biofrontera’s price is currently Undervalued.
Does Biofrontera pay dividends?
Biofrontera does not currently pay dividends.
What is Biofrontera’s EPS estimate?
Biofrontera’s EPS estimate is -0.12.
How many shares outstanding does Biofrontera have?
Biofrontera has 11,648,323 shares outstanding.
What happened to Biofrontera’s price movement after its last earnings report?
Biofrontera reported an EPS of $0.48 in its last earnings report, beating expectations of $0.195. Following the earnings report the stock price went down -1.498%.
Which hedge fund is a major shareholder of Biofrontera?
Currently, no hedge funds are holding shares in BFRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biofrontera
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
BFRI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong positive operational and strategic progress: record revenues, a highly profitable Q4 driven by a materially improved cost structure from the acquisition of U.S. assets, clear commercial execution with unit and lamp placement growth, and multiple positive clinical readouts with an imminent PDUFA for sBCC. Key near-term challenges remain — full-year GAAP losses and negative adjusted EBITDA, continued cash burn with modest year-end liquidity, elevated legal costs, and dependence on upcoming regulatory approvals. Management expects the full financial benefit of the new earn-out/cost structure to be realized in 2026, which, combined with the clinical pipeline and financing activity, supports a constructive outlook despite remaining execution and regulatory risks.View all BFRI earnings summariesBFRI Stock 12 Month Forecast
Average Price Target
$9.00
▲(1116.22% Upside)
Technical Analysis
Ownership Overview
2.06% Insiders
0.79% Mutual Funds
17.77% Other Institutional Investors
78.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---